Sutro Biopharma, Inc. · NASDAQ:STRO

Sutro Biopharma — Investor Presentation (September 2021)

25 slides from Sutro Biopharma's investor presentation, September 2021

  1. Slide 1: Company Overview

    Company Overview September 2021 Sutro Biopharma NASDAQ: STRO NON-CONFIDENTIAL

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state

  3. Slide 3: Pioneer and Leader in Cell-Free Technology

    Pioneer and Leader in Cell-Free Technology Expanding cell-free beyond ADCs Additional value creation 1 Multiple ADC through programs spinout Building showcasing ecosystem platform through breadth 1 New strategic modalities and Establish partnerships extended cell-free 1 value creation ecosystem 1 1

  4. Slide 4: Industry Leading Cell-Free Protein Synthesis Platform

    Industry Leading Cell-Free Protein Synthesis Platform GMP production yields consistent and scalable end-products IgG with Non- Grow Cells Cellular Cell-Free Protein Natural Amino Linker-Warhead Homogenous from E. Coli Cell Lysis Extract Synthesis Acids Click Chemistry ADC 1 2 3 4 5 6 7 Specific to p

  5. Slide 5: Advantages of Precision Protein Therapeutics

    Advantages of Precision Protein Therapeutics Homogenous, precisely designed complex biologics with optimized performance Challenges in Traditional Cell-Based Complex Advantages of Sutro’s Cell-Free Synthesis Biologics Discovery and Manufacturing Platform for Best-in-Class Biologics Performance Perfo

  6. Slide 6: Deep Arsenal of Tools in the R&D Pipeline Available to Attack Cancer

    Deep Arsenal of Tools in the R&D Pipeline Available to Attack Cancer (1) Novel and precise design to drive adaptive and protective immune responses Bispecific Antibody Conjugated Antibody Cytokine Derivative Prodrug Cytokine Modality Immune Cell Engager ADC or ISAC iADC Bispecific ADC Derivative Tar

  7. Slide 7: Cell-Free Platform Delivering Robust Pipeline

    Cell-Free Platform Delivering Robust Pipeline Four product candidates in the clinic and late-stage discovery programs Modality Program Target Indication Discovery Preclinical Phase 1/1b Phase 2/3 Partner Ovarian Fast Track Designation STRO-002 FolRα ADC Endometrial NSCLC Lymphomas Antibody-Drug STRO

  8. Slide 8: FolRα-Targeting ADC

    STRO 002 FolRα-Targeting ADC Potential Best-in-Class ADC for Ovarian and Endometrial Cancers NON-CONFIDENTIAL

  9. Slide 9: STRO-002 Potentially Best-in-Class ADC for Ovarian Cancers

    STRO 002 STRO-002 Potentially Best-in-Class ADC for Ovarian Cancers FolRα targeting ADC with tubulin inhibitor cytotoxin potentially providing immunogenic cell death 1 FolRα STRO-002 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 4, targeting folate- receptor alph

  10. Slide 10: STRO-002-GM1 Dose-Escalation Cohort Has Been Completed

    STRO 002 STRO-002-GM1 Dose-Escalation Cohort Has Been Completed Heavily pre-treated ovarian cancer patients with six median line of prior therapies Part 1: Dose-Escalation Cohort in Ovarian All Patients Baseline Characteristic N=39 All-Comers STRO-002 6.4 mg/kg 61 years Ovarian Cancer Median age N=3

  11. Slide 11: STRO-002 Was Generally Well Tolerated

    STRO 002 STRO-002 Was Generally Well Tolerated 86% of TEAEs remain Grade 1-2 and no observed ocular toxicity signal Dose Levels in Dose-Escalation Common TEAEs > 25% By Grade (2) Overall All Patients All Safety Evaluable Grade 1 Grade 2 Grade 3 Grade 4 Dose Levels (Q3W) (N=39) (N=39) Patients N (%)

  12. Slide 12: Tumor Reduction Observed in Majority of Patients

    STRO 002 Tumor Reduction Observed in Majority of Patients 10 patients met criteria for RECIST response including one CR Maximum Change (1) in Tumor Target Lesions (N=31) 20% RECIST- Objective Evaluable 0% Response per Population RECIST v1.1 (N=31) Responders 10 -30% Partial Response PRu PRu PRu PRu

  13. Slide 13: Tumor Regression and Control Over Time

    STRO 002 Tumor Regression and Control Over Time Deepening of responses and two patients with prolonged stable disease remaining on study Change in Sum of Diameters for Target Lesions Over Time (N=31) Change from baseline (%) 20 Best Overall Response (BOR) 0 PD SD PRu -30 PR CR Treatment ongoing as o

  14. Slide 14: Clinical Benefit Seen in Heavily Pre-Treated Patient Population

    STRO 002 Clinical Benefit Seen in Heavily Pre-Treated Patient Population Median duration of response is 5.8 months and three patients remained on study at over 18 months Treatment Duration (1) and Response, Based on Evaluable Patients (N=31) CR Dose Level PR 2.9 mg/kg 3.5 mg/kg CR Individual patient

  15. Slide 15: Favorable PFS Compared to Chemotherapy and Other Agents

    STRO 002 Favorable PFS Compared to Chemotherapy and Other Agents Based on Kaplan-Meier estimates, median PFS was 7.2 months Durability at a Median Study Follow-up of 8.4 Months Endpoint Median 95% CI PFS (1) (N=39) 7.2 months (4.5 months, 10.8 months) DOR (2) (N=5) 5.8 months (2.0 months, not evalua

  16. Slide 16: FolRα-Expression by Immunohistochemistry

    STRO 002 FolRα-Expression by Immunohistochemistry Responses and anti-tumor activity observed across various FolRα-expression levels Immunohistochemistry Data (1) for Patients Treated at ≥ 2.9 mg/kg Individual Patients (N=18) (Ventana FOLR1 assay) 300 295 Best Overall 235 245 Response (BOR) 210 H-sco

  17. Slide 17: Path Forward for STRO-002 Clinical Development

    STRO 002 Path Forward for STRO-002 Clinical Development Next steps for moving towards registration-directed study Part 2: Dose-Expansion Cohorts (Ovarian & Endometrial) First patient for Determine optimal efficacious dose-expansion dose that is well-tolerated and All-Comers Ovarian Cancer N≈20 STRO-

  18. Slide 18: CD74-Targeting ADC

    STRO 001 CD74-Targeting ADC Potential First and Best-in-Class ADC for B-Cell Malignancies NON-CONFIDENTIAL

  19. Slide 19: Potential First-in-Class Molecule for Patients with NHL and MM

    STRO 001 Potential First-in-Class Molecule for Patients with NHL and MM Stable CD74 targeting ADC for hematological cancers designed to minimize bystander effects 1 CD74 STRO-001 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 2, targeting CD74: 1• CD74 is expresse

  20. Slide 20: STRO-001-BCM1 Study Design and Updates

    STRO 001 STRO-001-BCM1 Study Design and Updates Ongoing Phase 1 dose-escalation study with NHL update at ASH 2020 STRO-001-BCM1 Dose-Escalation Study NHL Cohort Update at ASH 2020 R/R multiple myeloma A total of 21 patients have been treated with STRO-001 Cohort A RP2D (N=30) and 18 patients were ev

  21. Slide 21: ASH 2020 Update in NHL Cohort

    STRO 001 ASH 2020 Update in NHL Cohort Heavily pre-treated patient population with 5 median lines of prior therapies Baseline Characteristic (N=21) Patients With ≥1 Event, n (%) TEAEs by Grade, Age, median (range), years 64.5 (21–82) Occurring in ≥15% Grade 1 Grade 2 Grade 3 Grade 4 Time from diagno

  22. Slide 22: Encouraging Interim Treatment Duration and Responses

    STRO 001 Encouraging Interim Treatment Duration and Responses Partial responses in two DLBCL patients who had progressed on CAR-T Treatment Duration Responses to STRO-001 SD* Dose Demographics and Best Doses Duration of Level, Prior Therapies Individual patients with NHL treated PR Diagnosis Respons

  23. Slide 23: Financial Overview

    Financial Overview Well-capitalized through cash and other financial sources Projected cash runway into $283.4M in cash, cash equivalents & 2H 2023 , marketable securities not including potential monetization of as of June 30, 2021 Vaxcyte shares or future BD ~1.6M shares Funding received from our c

  24. Slide 24: Driving Value Through Advancing Programs

    Driving Value Through Advancing Programs Multiple opportunities to impact value into 2021 and beyond Program Indication Milestone Anticipated Timing Additional dose-escalation data ASCO 2021 ✔ Initial dose-expansion data 2H 2021 STRO-002 Ovarian Cancer Initiate combination study 2H 2021 FolRα ADC EO

  25. Slide 25: Experienced Leadership Team

    Experienced Leadership Team William Newell, JD Trevor Hallam, PhD Arturo Molina, Ed Albini Chief Executive Officer and President of Research and MD, MS, FACP Chief Financial Officer Member of the Board of Chief Scientific Officer Chief Medical Officer Directors Jane Chung, RPh Shabbir Anik, PhD Lind

Sutro Biopharma — Investor Presentation (September 2021) on 6ix